2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates

home / around-the-practice / 2022-asco-genitourinary-cancers-symposium-urothelial-cancer-updates

Expert panelists focus on a patient profile of metastatic urothelial cancer, discuss strategies and challenges for maintenance therapy, and comment on how recent clinical trial data presented at the 2022 ASCO Genitourinary Cancers Symposium may impact clinical practice for patients with the disease.

Recent Treatment Advances in Urothelial Cancer

EP. 1: Recent Treatment Advances in Urothelial Cancer

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
April 15th 2022

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).

Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

EP. 2: Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
April 15th 2022

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

The Role of Biomarkers in Immunotherapy Selection for mUC

EP. 3: The Role of Biomarkers in Immunotherapy Selection for mUC

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
April 21st 2022

Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.

JAVELIN Bladder 101: Study Design and Patient Outcomes

EP. 4: JAVELIN Bladder 101: Study Design and Patient Outcomes

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
April 21st 2022

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

EP. 5: Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 2nd 2022

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

Strategies and Barriers in mUC Maintenance Therapy

EP. 6: Strategies and Barriers in mUC Maintenance Therapy

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 2nd 2022

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

EP. 7: Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 9th 2022

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Maintenance Therapy Duration and Considerations for Treatment Interruption

EP. 8: Maintenance Therapy Duration and Considerations for Treatment Interruption

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 9th 2022

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Treatment Options After Progression on Frontline Maintenance Therapy

EP. 9: Treatment Options After Progression on Frontline Maintenance Therapy

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 13th 2022

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

EP. 10: Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 13th 2022

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

EP. 11: ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 23rd 2022

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

ASCO GU 2022 Updates: Antibody-Drug Conjugates

EP. 12: ASCO GU 2022 Updates: Antibody-Drug Conjugates

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 23rd 2022

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

EP. 13: ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 27th 2022

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Emerging Data and Future Directions in UC

EP. 14: Emerging Data and Future Directions in UC

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD
May 27th 2022

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Recap: Treatment Updates in Urothelial Cancer

EP. 15: Recap: Treatment Updates in Urothelial Cancer

Cancer Network Staff
June 12th 2022

Expert panelists focus on the treatment of metastatic urothelial cancer and discuss strategies and challenges for maintenance therapy.